Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Advisory Board

Ian J. Constable, MD
Chair

Dr. Constable is Founder and Professor of Ophthalmology at the Lions Eye Institute, University of Western Australia, and is an expert in gene therapy approaches to retinal disease.


Mark S. Blumenkranz, MD

Dr. Blumenkranz is Professor and Chairman at the Byers Eye Institute at Stanford. He is a renowned expert in retinal disease and has founded several Silicon Valley startup companies.


Steven D. Schwartz, MD

Dr. Schwartz is Professor of Ophthalmology and Chief of Retina Division at the UCLA Jules Stein Eye Institute. He is a renowned expert in retinal diseases and early-stage clinical research.


Judy Gordon, DVM

Dr. Gordon is a Clinical Regulatory Consultant with extensive experience in Ophthalmology products.


Steven Butler, PhD

Dr. Butler is a Consulting Biostatistician. As an Associate Director at Genentech, he served as the lead biostatistician and development sub-team leader for Lucentis.

Avalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer

July 1, 2014

MENLO PARK, Calif., July 1, 2014 -- Avalanche Biotechnologies, Inc., a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the appointment of Samuel B. Barone, M.D. in the role of Chief Medical Officer. Dr. Barone will lead the company’s clinical development programs, including advancing Avalanche’s lead product, AVA-101 for the treatment of wet AMD. Dr. Barone will report to Thomas Chalberg, Ph.D., Avalanche’s Co-Founder and Chief Executive Officer.

Read More

Read All Avalanche News